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The CYP3A4 enzyme is the most abundant human cytochrome P450 (CYP) and is
regarded as the most important enzyme involved in drug metabolism. Inter-individual
and inter-population variability in gene expression and enzyme activity are thought to be
influenced, in part, by genetic variation. Although Southern African individuals have been
shown to exhibit the highest levels of genetic diversity, they have been under-represented
in pharmacogenetic research to date. Therefore, the aim of this study was to identify
genetic variation within CYP3A4 in three South African population groups comprising of
29 Khoisan, 65 Xhosa and 65 Mixed Ancestry (MA) individuals. To identify known and
novel CYP3A4 variants, 15 individuals were randomly selected from each of the population
groups for bi-directional Sanger sequencing of ∼600 bp of the 5′-upstream region and
all thirteen exons including flanking intronic regions. Genetic variants detected were
genotyped in the rest of the cohort. In total, 24 SNPs were detected, including CYP3A4∗12,
CYP3A4∗15, and the reportedly functional CYP3A4∗1B promoter polymorphism, as well
as two novel non-synonymous variants. These putatively functional variants, p.R162W
and p.Q200H, were present in two of the three populations and all three populations,
respectively, and in silico analysis predicted that the former would damage the protein
product. Furthermore, the three populations were shown to exhibit distinct genetic
profiles. These results confirm that South African populations show unique patterns of
variation in the genes encoding xenobiotic metabolizing enzymes. This research suggests
that population-specific genetic profiles for CYP3A4 and other drug metabolizing genes
would be essential to make full use of pharmacogenetics in Southern Africa. Further
investigation is needed to determine if the identified genetic variants influence CYP3A4
metabolism phenotype in these populations.
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INTRODUCTION
The human CYP3A enzymes are regarded as the most promi-
nent Cytochrome P450 (CYP) subfamily in facilitating the
elimination of drugs, other xenobiotic compounds and
endogenous molecules from the body (Lamba et al., 2002).
The pharmacogenetically relevant CYP3A4 is responsible
for metabolizing 50–60% of all clinically prescribed drugs
(Guengerich, 1999) and is listed among The Pharmacogenetics
and Pharmacogenomics Knowledge Base’s (PharmGKB’s) “very
important pharmacogenes” (http://www.pharmgkb.org/gene/
PA130?tabType=tabVip). CYP3A4 can be inhibited by drugs
(e.g., ketoconazole and ritonavir) and is often involved in
unfavorable drug-drug interactions, due to its ability to accom-
modate two or more similar or dissimilar molecules in its active
site (Sevrioukova and Poulos, 2013). The enzyme is predomi-
nantly expressed in the liver and small intestine (Shimada and
Guengerich, 1989). Expression has as much as 40-fold variation
between individual human livers and a 10-fold variation in
the metabolism of CYP3A4 substrates in vivo (Shimada and
Guengerich, 1989; Lown et al., 1995; Guengerich, 1999). While
complex regulatory pathways and environmental factors are
important, it is suspected that a portion of this inter-individual
variation can be attributed to genetic variants located within the
coding gene regions as well as its core regulatory regions, which
affect either the expression level or the functional protein of the
gene (Steimer and Potter, 2002; Lamba et al., 2002).
Few pharmacogenetically-relevant polymorphisms have been
identified in the CYP3A4 gene; however, some polymorphisms
have been associated with, amongst others, immunosuppres-
sant dose requirements (Elens et al., 2011), clopidogrel response
variability (Angiolillo et al., 2006), and withdrawal symptoms
and adverse reactions in patients receiving methadone treatment
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(Chen et al., 2011). Furthermore, a rare haplotype, CYP3A4∗20,
results in a complete loss of function (Westlind-Johnsson et al.,
2006), while CYP3A4∗1B is suspected to alter the expression
levels of CYP3A4 (Westlind et al., 1999), although conflicting
results have been reported (Wang et al., 2011). Although genetic
variants in the CYP3A4 gene have been extensively studied in
populations such as Caucasians, Asians, and African-Americans,
little research has been conducted in present-day African pop-
ulations, including those indigenous to South Africa (Warnich
et al., 2011). Not only are these research disparities observed
in candidate gene studies, but they also extend to recent large
scale re-sequencing projects such as the 1000 Genomes Project,
which although comprehensively examining the genomic varia-
tion present in many individuals, provides no information for
South African populations (1000 Genomes Consortium, 2010).
We have therefore tried to aid in addressing the disparity
of pharmacogenetic data that exists for South African popu-
lations by analyzing three of the diverse population groups,
which are representative of: (1) the most ancient population
group: the Khoisan, (2) the most globally-admixed population
group: the South African Mixed Ancestry (MA) population,
and (3) the largest language family in South Africa: the Bantu-
speaking population group, represented by the Xhosa population.
The ancient Khoisan population used in this study consisted of
individuals from the !Kung and Khwe linguistic groups (Chen
et al., 2000). These individuals are descendant from people of
the latter Stone Age and are believed to be some of the first lin-
eages of Homo sapiens (Kaessmann and Pääbo, 2002). The MA
population, with Xhosa, Khoisan, European, and Asian ances-
tral contributions, has been shown to exhibit the highest levels of
admixture across the globe (Tishkoff et al., 2009) and is therefore
of interest for pharmacogenetic applications as genetic variants
present inmany different populationsmay affect these individuals
as has been reported for other admixed populations such as those
from Brazil (Suarez-Kurtz, 2005, 2010; Suarez-Kurtz et al., 2012).
Lastly, 9 of the 11 official South African languages are classified
as Bantu languages (Warnich et al., 2011), spoken by ∼75% of
the total South African population, and therefore it is imperative
that representatives of this group are included in pharmacoge-
netic research. In this study, we utilized the Xhosa population,
which are representative of the Nguni-speaking tribes (Warnich
et al., 2011) and are the biggest Bantu-speaking population in the
Western Cape of South Africa, where this research was conducted.
In our experience, it is important that pharmacogenes, such
as the CYP genes are comprehensively characterized in South
African populations, as we have discovered both novel alleles and
unique variation profiles for the CYP2C19 and CYP2D6 genes
(Drögemöller et al., 2010; Wright et al., 2010). It is hoped that the
comprehensive characterization of CYP3A4 in these populations
will aid future CYP3A4 genotype-phenotype studies in African
populations to determine whether functionally relevant CYP3A4
polymorphisms exist that have an impact on drug metabolism
phenotype. We therefore screened the 5′-flanking region and
thirteen exonic regions of the CYP3A4 gene in the three South
African populations described above in order to determine which
common allelic variants, novel or previously characterized, are
present.
MATERIALS ANDMETHODS
CLINICAL SAMPLES
Ethical approval was obtained for this study from the Human
Research Ethics Committee of Stellenbosch University
(S12/07/190) and informed consent was acquired from all
participants. Genomic DNA (gDNA) was available for 29
Khoisan, 65 Xhosa, and 65 MA healthy individuals. The Khoisan
samples used in this study were collected from !Kung and
Khwe speaking individuals from the Schmidtsdrift region of the
Kalahari desert in the Northern Cape Province of South Africa
(Chen et al., 2000), while samples from the Xhosa and MA
populations were collected from the Western Cape Province of
South Africa.
POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION
Primers were designed to amplify ∼600 bp of the 5′-upstream
region and all 13 exons with flanking intronic regions of CYP3A4
(GenBank: AF280107.1; Ensembl ID: ENSG00000160868) (refer
to Table 1 for primer sequences). PCR amplifications were car-
ried out in a total reaction volume of 25µl, with each reac-
tion containing 20–30 ng of gDNA, 10 pmol of each primer,
320µMdNTPs, 4mMMgCl2, 0.5U BIOTAQ™DNA polymerase
and 1X Reaction Buffer. All reagents were supplied by Bioline,
London, UK. The reaction cycle conditions consisted of an ini-
tial denaturation step at 94◦C for 3min, followed by 30 cycles
of 15 s denaturation at 94◦C, 15 s annealing at varying tem-
peratures (refer to Table 1 for specific annealing temperatures),
and 30 s extension at 72◦C, with a final extension at 72◦C
for 5min.
DNA SEQUENCING
To identify common CYP3A4 genetic variation occurring in each
of the three populations, 15 individuals were randomly selected
from every population groups for bi-directional sequence anal-
ysis, allowing for detection of alleles with a frequency of more
than 10%, with 95% confidence. The PCR products from each of
the 13 amplicons were purified with SureClean (Bioline) and bi-
directionally sequenced using the BigDye® Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, CA, USA), after which cap-
illary electrophoresis was performed by the Central Analytical
Facility of Stellenbosch University on a 3130xl Genetic Analyser
(Applied Biosystems). The obtained sequences were subsequently
compared to the reference sequence (GenBank: AF280107.1;
Ensembl ID: ENSG00000160868) to detect the presence of vari-
ants. The generated sequence data also served to ensure that
the reaction conditions used did not amplify any of the associ-
ated CYP3A4 isoforms or pseudogenes. The effect of the detected
variants was determined using the software programs Sorting
Intolerant From Tolerant (SIFT), Polymorphism Phenotyping
(PolyPhen) and the Alternative Splice Site Predictor (ASSP)
(http://www.es.embnet.org/~mwang/assp.html; Ramensky et al.,
2002; Ng and Henikoff, 2003).
GENOTYPING OF THE DETECTED VARIANTS
To determine the frequencies of the genetic variants detected in
the 5′-flanking region and the coding regions of the CYP3A4
gene through sequence analysis, an additional 14 individuals from
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Table 1 | Sequencing Primers and PCR conditions.
Region Primer name Sequence (5′-3′) Tm (◦C) Product size (bp)
5′-upstream
5′_F CAG AAG GGA TGA CAT GCA GA
60 767
5′_R GGC TAT GTG CAT GGA GCT TT
Exon 1
E1_F GAT TCT TTG CCA ACT TCC AAG
60 363
E1_R GAT TAG CAC CCC AAG TCC AA
Exon 2
E2_F GCA GGA AAG GAC CTG ATG AA
60 323
E2_R AAG CTG CTC TTG GCA ATC AT
Exon 3
E3_F TGA CGT CTC CAA ATA AGC TTC C
60 301
E3_R AGG TTG ACA AGA GCT TCA TCC
Exon 4
E4_F AGG ATC AAA GTC TGG CTT CC
60 305
E4_R GGA TGA AGT GGA CGT GGA AC
Exon 5
E5_F TCT AGC ATA GGG CCC ATC AC
60 352
E5_R CA GTG GAC TAC CCC TTG GAA
Exon 6
E6_F CCA AGG GGT AGT CCA CTG AA
55 362
E6_R GGA ATA ACC CAA CAG CAG GA
Exon 7
E7_F TGG AGT GTG ATA GAA GGT GA
55 516
E7_R TTG TGA CAG GGG GCT GAT AG
Exon 8
E8_F TGC TCC AGG TAA ATT TTG CAC
60 369
E8_R CAA ACC CCA CTT TCT GCA TT
Exon 9
E9_F CAT CCT GCT TTC CAA GGA
60 418
E9_R CCT GCA TGC CTC TAG AAA GTG
Exon 10
E10_F TGA TGC CCT ACA TTG ATC TGA
60 391
E10_R CTG CCA GTA GCA ACC ATT TG
Exon 11
E11_F CCC GAA TGC TTC CCA CCT
60 506
E11_R GGC AGA ATA TGC TTG AAC CAG
Exon 12
E12_F GAC TGA AAG CTC CTA TAG TGT C
60 598
E12_R CCA TGC TAA TCT ACA TGG GCT
Exon 13
E13_F GCC ATC ATA CCT AAT AAT CTG G 60 Xhosa
988
E13_R AT GTG CAG GAA AGC ATC TGA 55 Others
5′, 5′-upstream; E, exon; F, forward; R, reverse.
the Khoisan population and 50 individuals each from the Xhosa
and MA populations were genotyped using a combination of
restriction fragment length polymorphism (RFLP) analysis and
additional sequence analyses. In cases where no restriction sites
were created or destroyed by the SNPs of interest, mutagenic
primers were designed to introduce artificial restriction enzyme
recognition sequences (refer to Table 2 for the primer sequences
used for RFLP genotyping). Amplification using the mutagenic
primers was performed by means of a nested PCR, using 1 in 200
dilutions of PCR product as template, to avoid co-amplification
of isoforms and pseudogenes. The nested PCR conditions were
identical to those used during original PCR amplification, except
that the cycle number and MgCl2 concentration were changed to
25 cycles and 2mM, respectively (refer to Table 2 for annealing
temperatures). To ensure that the RFLP assays were successful,
samples with known genotypes were selected as controls for each
of the individual restriction enzyme analyses. Due to the large
number of variants detected in the exon 7 amplicon, all the indi-
viduals from all three of the population groups were sequenced
for this region, rather than utilizing individual RFLP genotyp-
ing assays. Additionally, due to the fact that the RFLP genotyping
assay for rs57409622 in exon 6 would detect both the presence
of this SNP and the adjacent rs4986907 (allele defining SNP of
CYP3A4∗15), any individuals testing positive for this assay under-
went bi-directional sequencing to determine which one, or both,
of the SNPs were in fact present. For genotyping specifications,
including a list of the specific restriction enzymes used, refer to
Table 2.
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STATISTICAL ANALYSIS
Allele frequencies of the CYP3A4 genetic variants detected in
the three population groups were compared using MedCalc
Version 12.3.0 (http://www.medcalc.org/calc/odds_ratio.php).
Furthermore, we compared the frequencies of the allele defining
SNPs detected in the three South African populations to the fre-
quencies reported by the 1000 Genomes Browser (http://browser.
1000genomes.org/) and HapMap Phase I + II Project data
(http://hapmap.ncbi.nlm.nih.gov/). The 1000 Genomes Browser
contains allele frequency information for the African (AFR),
American Admixed (AMR), East Asian (ASN) and European
(EUR) populations; while the HapMap project contains fre-
quency data for European (CEU), Chinese (CHB), Japanese
(JPT) and Nigerian (YRI) populations. Deviations from Hardy-
Weinberg equilibrium (HWE) were determined using either a
Pearson chi-squared analysis or an analogue to Fisher’s exact
test, depending on observed genotype distribution, in Tools
for Population Genetic Analysis (TFPGA) Software v1.3 (http://
www.marksgeneticsoftware.net/tfpga.htm). P-values of <0.05
were considered statistically significant.
RESULTS
VARIANT DETECTION
This study detected 24 SNPs in 45 individuals from three South
African populations using CYP3A4 DNA sequencing. Three of
the intronic SNPs and one SNP in the 5′-flanking region are
novel. Genotyping of rs12721624 in intron 8 and rs147972695 in
intron 12 could not be performed in the entire cohort, due to
technical difficulties. Genotyping of the remaining 22 SNPs was
successful, and all SNPs were in HWE (refer to Table 3 for the
positions and frequencies of the detected SNPs). The previously
described alleles CYP3A4∗1B and ∗1G were present in all three
populations, while CYP3A4∗12 and CYP3A4∗15 were only present
in the Xhosa population. Furthermore, two novel alleles, desig-
nated CYP3A4∗23 and CYP3A4∗24, which are characterized by the
two non-synonymous SNPs, resulting in p.R162W and p.Q200H,
were detected. CYP3A4∗24 was present in all three population
groups, while CYP3A4∗23 was present in the Xhosa and Khoisan
populations. Of particular interest, the amino acid change caused
by R162W (CYP3A4∗23) was predicted by both the SIFT and
PolyPhen algorithms to affect the function of the protein product.
None of the variants were predicted to alter any splice-sites.
POPULATION VARIANT FREQUENCY COMPARISONS
When examining the successfully genotyped variants in the three
South African populations, we noticed that the allele frequen-
cies for several SNPs differed significantly between the population
groups (P < 0.05) (refer to Table 4). The smallest difference was
seen when the allele frequencies of the Khoisan and Xhosa popu-
lations were compared, with the allele frequencies of three SNPs
differing significantly between these two population groups. With
regards to the comparisons of (1) the Khoisan and MA popula-
tions, and (2) the Xhosa and MA populations, five and six SNPs
showed significant allele frequency differences, respectively.
The novel CYP3A4 alleles, although detected in the South
African populations (refer to Table 3), were present at frequencies
of less than 1% in the populations recorded on the 1000 Genomes
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Table 3 | CYP3A4 variants detected in the three South African populations.
Position in gene Allele rs number Region Amino acid Allele frequencies (%)
substitution
(ENSG00000160868) Khoisan Xhosa MA
(n = 29) (n = 65) (n = 65)
−392 A>GG>A CYP3A4*1B rs2740574 5′-flanking 76.79 73.02 45.90
−292 T>G Novel 5′-flanking 7.14 0.00 0.81
−215 T>A rs144721069 5′-flanking 0.00 0.81 0.85
3847 A>G Novel Intron 1 0.00 8.59 0.00
5916 T>C rs12721625 Intron 2 0.00 1.56 1.56
13969 G>A Novel Intron 5 0.00 0.00 2.31
14268 C>T CYP3A4*23 rs57409622 Exon 6 R162W 3.57 0.77 0.00
14269 G>A CYP3A4*15 rs4986907 Exon 6 R162Q 0.00 2.38 0.00
15619 A>G rs111768354 Exon 7 G190G 1.72 3.85 3.17
15628 C>T rs4987159 Exon 7 I193I 0.00 4.62 3.17
15649 A>T CYP3A4*24 rs113667357 Exon 7 Q200H 10.34 3.08 3.17
15753 T>G rs2687116 Intron 7 75.86 77.69 45.38
15783 T>C rs4987160 Intron 7 10.34 3.85 3.85
15804 T>G rs28988584 Intron 7 0.00 3.85 2.38
15837 T>A rs12721622 Intron 7 10.34 10.00 3.85
17024 C>T* rs12721624 Intron 8 0.00 0.00 3.33
17829 T>C Novel Intron 9 8.62 0.78 0.78
20230 G>A CYP3A4*1G rs2242480 Intron 10 91.38 93.85 60.00
20309 G>C rs4986911 Intron 10 15.52 9.68 6.35
20327 T>C rs34738177 Intron 10 0.00 1.61 0.78
21896 C>T CYP3A4*12 rs12721629 Exon 11 L373F 0.00 2.34 0.00
23081 C>T rs12721620 Intron 11 1.92 20.31 10.83
25721 A>G rs3735451 Intron 12 76.92 87.70 50.00
25739 C>T* rs147972695 Intron 12 0.00 3.33 0.00
Allele frequencies are given for the variant allele.
*Due to RFLP genotyping failure, these SNPs were only genotyped in the 45 sequenced individuals.
Browser. When examining the previously described CYP3A4 alle-
les, in the case of CYP3A4∗12 and CYP3A4∗15, the data from
the 1000 Genomes Browser was not available for all populations,
therefore we utilized frequency data from the HapMap Project.
Both of these variants were not detected in any of the HapMap
populations, however, it should be noted that frequency data for
the CYP3A4∗15 SNP was not available for the YRI population.
These SNPs were also absent in the MA and Khoisan popula-
tions, but were present in the Xhosa population at a frequency
of at 2.3% and 2.4%, respectively. With regards to the remain-
ing potentially functional CYP3A4 allele, namely CYP3A4∗1B, the
frequencies of this variant in the three South African populations
as well as those reported by the 1000 Genomes Browser differed
substantially, as demonstrated by Figure 1.
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FIGURE 1 | Distribution of the CYP3A4∗1B allele frequencies in all three South African populations and the four populations present in the 1000
Genomes Browser. (AFR, African; AMR, American Admixed; ASN, East Asian; EUR, European).
DISCUSSION
CYP3A4 GENETIC VARIATION IN THE THREE SOUTH AFRICAN
POPULATIONS
To our knowledge, this was the first study in which the entire
coding region of the CYP3A4 gene was screened for common
genetic variation in any Southern African population. This study
identified a total of 24 variants in the three South African popu-
lation groups, which included the discovery of four novel SNPs
(i.e., ∼17% of the total genetic variation). Overall this study
revealed the presence of the previously described CYP3A4∗1B,
CYP3A4∗1G, CYP3A4∗12, and CYP3A4∗15 alleles, in addition to
two novel alleles, CYP3A4∗23 and CYP3A4∗24. The number of
novel alleles reported here is in accordance with the number of
novel alleles that we have detected previously through the re-
sequencing of other CYP genes in South African populations
(Drögemöller et al., 2010; Wright et al., 2010). Prior to this
study, these novel CYP3A4 alleles had not been recorded on
the CYP allele database and were present at very low frequen-
cies in the populations described on the 1000 Genomes Browser.
Both were present in the Xhosa and Khoisan populations exam-
ined in this study and CYP3A4∗24 was additionally detected in
the MA population. The p.R162W amino acid change in exon
6, characterizing CYP3A4∗23, may have functional consequences
for the CYP3A4 protein, as arginine is a positively charged and
hydrophilic amino acid; while tryptophan is a polar, aromatic and
hydrophobic amino acid. The likely functional consequences of
this variant are in agreement with the predictions made by both
the SIFT and PolyPhen algorithms. Although the p.Q200H vari-
ant, characterizing CYP3A4∗24, was not predicted to change the
function of the protein product, the presence of this variant has
also been reported in the genome of another Khoisan individ-
ual sequenced by Schuster et al. (2010), which correlates to the
fact that the frequencies of both novel alleles were highest in
the Khoisan population (Drögemöller et al., 2011). Additionally,
the low frequency of these variants in the 1000 Genomes popu-
lations in comparison to the presence of these alleles at varying
frequencies in the South African population groups, highlights
the unique genomic composition of South African populations.
Thus, results obtained from other population groups cannot be
directly inferred onto the South African populations and com-
prehensive re-sequencing studies such as this one are required to
characterize South African genomes.
The recent discovery of the CYP3A4∗22 allele confirmed
that novel alleles may have functional relevance to the field of
pharmacogenetics (Wang et al., 2011). This allele was initially
found to influence RNA expression and statin dose requirement
(Wang et al., 2011). These findings have subsequently been
replicated with regards to statin therapy and the allele has
additionally been shown to influence the dose requirements of
the immunosuppressants, tacrolimus, and cyclosporine (Elens et
al., 2011, 2012). CYP3A4∗22 is characterized by the intron 6 SNP
rs35599367, which, however, was not genotyped in the current
study as the aim of the study was to examine only coding regions,
including the exon-intron boundaries, and the core promoter
region of the gene. Furthermore, this variant does not occur in
the 1000 genomes AFR or ASN populations and occurs at very
low frequencies (2–5%) in the EUR and AMR populations and is
thus unlikely to occur at pharmacogenetically relevant frequen-
cies in the South African populations (http://browser.1000geno
mes.org/Homo_sapiens/Variation/Population?r=7:993658169936
6816;source=dbSNP;v=rs35599367;vdb=variation;vf=11936818).
The reported functional significance of this intronic CYP3A4∗22
variant does, however, highlight the importance of non-coding
regions. The significance of these areas, including regions that are
not in close proximity to the gene has been further emphasized
by the recent release of the ENCODE data (ENCODE Project
Consortium et al., 2012). These data suggest that in the future
additional analyses to examine the variation present in such
areas, including the functional significance of the four novel
non-coding SNPs identified by this study, are warranted.
The detection of novel variants in this study highlights
the fact that although large re-sequencing studies such as the
1000 Genomes Project have played an integral role in char-
acterizing the human variome (1000 Genomes Consortium,
2010), novel variation still exists, underlining the importance
of re-sequencing studies such as this one. These re-sequencing
studies are specifically required in African populations, as these
populations have been under-represented in genomic studies
to date (Rosenberg et al., 2010; Drögemöller et al., 2011).
Furthermore, it may be important to compare results obtained
by next generation sequencing studies to those obtained through
the use of Sanger sequencing. Although the throughput of next
generation sequencing studies is beyond comparison, it may be
beneficial to evaluate the accuracy of next generation sequencing
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for the complex and polymorphic CYP genes, whose sequences
show high similarity to one another and to their corresponding
pseudogenes (Drögemöller et al., 2011). This may be particularly
important with regards to the genotyping of CYP3A4, which
shows between 76 and 88% sequence similarity to the CYP3A43,
CYP3A5, and CYP3A7 genes (http://www.ensembl.org/Homo_
sapiens/Gene/Compara_Paralog?g=ENSG00000160868;r=7:9935
4604-99381888) and is thus likely to be affected by the con-
sequences of misalignment or co-amplification of other genes
during the use of high-throughput technologies.
Of the previously identified alleles that were detected in this
study, both CYP3A4∗1B and CYP3A4∗12 have been reported to
have functional relevance for pharmacogenetic applications. The
high frequency CYP3A4∗1B is characterized by a 5′-upstream
c.−392A>G point mutation in a regulatory element, namely the
putative nifedipine-specific element, which has been linked to
altered gene expression in vitro (Amirimani et al., 2003; Georgitsi
et al., 2011). Furthermore, this allele has been associated with
various disease states such as prostate cancer and secondary
leukemias (Lamba et al., 2002). Of relevance to pharmacoge-
netic applications, PharmGKB lists this SNP as affecting the
metabolism of a number of therapeutic drugs, although the level
of evidence for variant-drug associations is still low currently
(http://www.pharmgkb.org/rsid/rs2740574; Whirl-Carrillo et al.,
2012). The lack of pharmacogenetic evidence for this allele is fur-
ther questioned by the results obtained by Wang et al. (2011)
and the functional significance of this variant may require fur-
ther examination. On the other hand, while CYP3A4∗1B appears
to affect the expression of CYP3A4, CYP3A4∗12 (p.L373F) affects
the protein product. p.L373 has been identified as one of the key
residues affecting substrate binding, cooperativity and regioselec-
tion of metabolism (Sevrioukova and Poulos, 2013) and therefore
the amino acid change has been shown to result in a protein that
amongst others, displays an altered testosterone metabolite pro-
file and a four-fold increase in theKm value for 1′-OHmidazolam
formation (Eiselt et al., 2001). While CYP3A4∗1B occurs at a rela-
tively high frequency, both CYP3A4∗12 and CYP3A4∗15 occur at
low frequencies, possibly limiting the relevance that these two
variants may have for pharmacogenetic applications, especially
when considering their absence from the HapMap populations.
Similarly, the lack of applicability of the SNPs definingCYP3A4∗3,
CYP3A4∗13, CYP3A4∗17, and CYP3A4∗18 to pharmacogenetics in
the South African setting is also likely as they were not detected
in this study or a previous study (Ikediobi et al., 2011). These
conclusions should however, be made with caution, as the rela-
tively frequent occurrence of rare variants in African populations
(Tishkoff et al., 2009) cannot be ignored and the effect of such
variants should possibly also be taken into account when con-
sidering the implementation of pharmacogenetics in the African
context.
VARIANT FREQUENCY DIFFERENCES BETWEEN THE THREE SOUTH
AFRICAN POPULATIONS
When comparing the significant differences in allele frequencies
between the three population groups, it was observed that the
three groups differed significantly from one another for eight
SNPs (refer to Table 4). These results reflect the unique genomic
compositions of South African populations (Warnich et al., 2011)
and indicate that the results of one South African population
are not always representative of another South African popula-
tion. When looking at the three populations independently, the
Khoisan and Xhosa were shown to be the most similar to one
another, while the differences observed between the Khoisan and
MA and the Xhosa and MA were comparable. The fact that the
MA population showed the greatest number of genetic differences
may be explained by the large number of ancestry contribu-
tions, other than the Xhosa and Khoisan, that have been made
to this population (Schlebusch et al., 2009; De Wit et al., 2010;
Quintana-Murci et al., 2010; Warnich et al., 2011). The large
degree of similarity observed between the Xhosa and Khoisan is
to be expected and can be explained by the large ancestry contri-
bution that the Khoisan have made to the Xhosa population (De
Wit et al., 2010; Warnich et al., 2011).
The differences in allele frequencies observed for the
CYP3A4∗1 sub-allele, CYP3A4∗1B, between the different popula-
tion groups (refer to Figure 1), serves as an excellent illustration
of how pharmacogenetic applications may differ between popu-
lation groups. It is important to remember that drugs designed
to optimally treat one population group based on the pres-
ence of a certain allele, may be harmful to another population
group for which the opposite allele is dominant. Figure 1 shows
how the CYP3A4∗1B allele is more frequent in the African pop-
ulations (Khoisan, Xhosa and AFR), while in the ASN and
EUR population groups the opposite allele occurs more often.
Interestingly, both the MA and AMR admixed populations show
allele frequencies that are intermediate between the African and
EUR/ASN populations. Furthermore, the MA is more similar to
the African populations, while the AMR is more similar to the
non-African populations. These results are in accordance with
the ancestral history of these population groups. The MA have
ancestry contributions from the Xhosa, Khoisan, European, and
Asian populations (Schlebusch et al., 2009; Tishkoff et al., 2009;
De Wit et al., 2010; Quintana-Murci et al., 2010), which explains
why although the frequencies of the variants in this population
are between the African and EUR/ASN populations, they are
more similar to the African populations. On the other hand, the
AMR population, which consists of the Mexicans, Puerto Ricans,
Columbians, and Peruvians (http://www.1000genomes.org/faq/
which-populations-are-part-your-study), is more similar to the
EUR/ASN population groups due to the larger ancestry con-
tribution that these populations have made to the AMR, when
compared to the ancestry contribution of Africans (Galanter et
al., 2012).
The allele frequency differences observed in admixed pop-
ulations, as previously reported in admixed Brazilian popula-
tions (Suarez-Kurtz, 2005, 2010; Suarez-Kurtz et al., 2012), bring
to light an important consideration for the implementation of
pharmacogenetics. Individuals within admixed populations are
likely to exhibit different levels of ancestry contributions, as has
been shown with the use of STRUCTURE analyses for both the
MA (Tishkoff et al., 2009) and Brazilian populations (Suarez-
Kurtz, 2010). Population based pharmacogenetic testing is thus
unlikely to detect all pharmacogenetically relevant variants and
it may be necessary to implement pharmacogenetics on an
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individualized level. In the context of South Africa with its diverse
population groups, which exhibit both rare variants and variants
from several different population sources (Warnich et al., 2011),
this may be especially important. However, before this goal can
be realized it will be necessary to consider whether individualized
treatment will be feasible in the resource limited settings of the
country.
CONCLUSIONS
Although this study identified both novel and known SNPs of
functional significance in all three population groups, due to
the current lack of validated evidence regarding the pharma-
cogenetic application of CYP3A4, the relevance of these SNPs
in the clinical setting remains unknown. The SNP markers
detected in the current study should therefore be included
in genotyping panels in future pharmacogenetic association
studies involving CYP3A4 substrate medications. Nonetheless,
this study provides an excellent example of how re-sequencing
studies are required in African populations in order to iden-
tify variation that remains novel. These differences in allele
frequencies were not only seen when comparing the South
African populations to other populations, but also when com-
paring them to each other. These results demonstrate that
a one-size-fits-all approach is not ideal when implementing
therapeutic treatment regimes, also within the South African
context.
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